Labile iron in parenteral iron formulations: A quantitative and comparative study

Nephrology Dialysis Transplantation

Volumn 19, Issue 3, 2004, Pages 561-565

  Van Wyck, David B ^a,c   Anderson, Jaime ^b   Johnson, Kevin ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b J2 Laboratories   (United States)

^c Kidney Health Institute LLC   (United States)

Author keywords

Adverse effects; Ferric glucomate; Iron; Iron dextrain; Iron sucrose; Transferrin

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON DERIVATIVE; IRON DEXTRAN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ARTICLE; BACTERIAL GROWTH; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; DRUG FORMULATION; IN VITRO STUDY; IRON THERAPY; MOLECULAR SIZE; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY;

BIOLOGICAL ASSAY; CHEMISTRY, PHARMACEUTICAL; FERRIC COMPOUNDS; HUMANS; IRON; IRON-DEXTRAN COMPLEX; PROTEIN BINDING; SUCROSE; TRANSFERRIN;

EID: 1342306211     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg579     Document Type: Article

References (19)

1. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280
2. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736
3. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
4. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002; 32 [Suppl 1]: 42-49
5. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834
6. Michelis R, Gery R, Sela S et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18: 924-930
7. Beshara S, Lundqvist H, Sundin J et al. Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 1999; 104: 296-302
8. Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 2001; 37: 879-883
9. Beshara S, Sorensen J, Lubberink M et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003; 120: 853-859
10. Kanakakorn K, Cavill I, Jacobs A. The metabolism of intravenously administered iron-dextran. Br J Haematol 1973; 25: 637-643
11. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002; 22: 479-487
12. Seligman PA, Schleicher RB, Pringle J. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999; 45: 898 901
13. Jacobs JC, Alexander NM. Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem 1990; 36: 1803-1807
14. Visseren FL, Verkerk MS, van der BT et al. Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. Eur J Clin Invest 2002; 32 [Suppl 1]: 84-90
15. Sahlstedt L, von Bonsdorff L, Ebeling F, Ruutu T, Parkkinen J. Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients. Br J Haematol 2002; 119: 547-553
16. Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H. Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 2003; 65: 1973-1978
17. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876
18. Feldman HI, Santanna J, Guo W et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
19. Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in predialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361